Colitis and chronic bleeding in patients treated with dasatinib

Dasatinib is a key therapeutic option in patients with chronic myeloid leukemia. Previous case reports associated it with acute colitis. This is another report that demonstrates a link between dasatinib and chronic colitis akin to inflammatory bowel disease, in patients undergoing therapy with dasatinib for a prolonged time.

[1]  Kotaro Suzuki,et al.  Clinical efficacy of fecal occult blood test and colonoscopy for dasatinib-induced hemorrhagic colitis in CML patients. , 2017, Blood.

[2]  A. Shakespeare,et al.  Dasatinib-Induced T-Cell-Mediated Colitis: A Case Report and Review of the Literature , 2016, Acta Haematologica.

[3]  H. Sone,et al.  Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study , 2013, Hematological oncology.

[4]  B. Sriha,et al.  Severe hemorrhagic colitis in a patient with chronic myeloid leukemia in the blastic phase after dasatinib use. , 2013, World journal of gastrointestinal pathophysiology.

[5]  G. Langman,et al.  Haemorrhagic Colitis Caused by Dasatinib , 2012, Case reports in hematology.

[6]  D. Greco,et al.  Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia. , 2012, Experimental hematology.

[7]  A. Safdar,et al.  Characteristics of, and risk factors for, infections in patients with cancer treated with dasatinib and a brief review of other complications , 2012, Leukemia & lymphoma.

[8]  N. Komatsu,et al.  [Hemorrhagic colitis caused by dasatinib following cytomegalovirus enterocolitis in a patient with chronic myelogenous leukemia in the second chronic phase]. , 2011, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[9]  S. Miyawaki,et al.  [Clinical profiles of 7 patients with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib]. , 2010, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[10]  A. Yang,et al.  The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib , 2009, Journal of hematology & oncology.

[11]  H. Kantarjian,et al.  Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy , 2009, Cancer.